Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company. It is focused on developing medicines, referred to as Bicycles(R) for diseases which are underserved by existing therapeutics. Bicycle Therapeutics plc is based in Cambridge, United Kingdom.
| Revenue (Most Recent Fiscal Year) | $72.86M |
| Net Income (Most Recent Fiscal Year) | $-218.96M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.69 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.44 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -166.52% |
| Net Margin (Trailing 12 Months) | -169.75% |
| Return on Equity (Trailing 12 Months) | -26.02% |
| Return on Assets (Trailing 12 Months) | -22.30% |
| Current Ratio (Most Recent Fiscal Quarter) | 12.09 |
| Quick Ratio (Most Recent Fiscal Quarter) | 12.09 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $7.21 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.15 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.16 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.03 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 70.09M |
| Free Float | 54.67M |
| Market Capitalization | $224.30M |
| Average Volume (Last 20 Days) | 0.41M |
| Beta (Past 60 Months) | 1.59 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 22.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 86.15% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |